-
Clopidogrel Plus Aspirin vs Aspirin Alone in Patients With Acute Mild to Moderate Stroke: The ATAMIS Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-11 Hui-Sheng Chen, Yu Cui, Xin-Hong Wang, Yu-Tong Ma, Jing Han, Ying-Jie Duan, Jiang Lu, Li-Ying Shen, Yong Liang, Wei-Zhong Wang, Hui Wang, Yong Zhao, Jin-Tao Zhang, Yu-Lin Song, Xiao-Mei He, Run-Hui Li, Ding-Bo Tao, Jing Li, Shu-Man Huang, Ni Wang, Mei Hong, Chong Meng, Wei Zhang, Duo-Lao Wang, Thanh N Nguyen
Dual antiplatelet therapy has been demonstrated to be superior to single antiplatelet in reducing recurrent stroke among patients with transient ischemic attack or minor stroke, but robust evidence for its effect in patients with mild to moderate ischemic stroke is lacking.
-
Emerging Cerebrospinal Fluid Biomarkers of Disease Activity and Progression in Multiple Sclerosis. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-11 Anne H Cross, Jeffrey M Gelfand, Simon Thebault, Jeffrey L Bennett, H Christian von Büdingen, Briana Cameron, Robert Carruthers, Keith Edwards, Robert Fallis, Rachel Gerstein, Paul S Giacomini, Benjamin Greenberg, David A Hafler, Carolina Ionete, Ulrike W Kaunzner, Lay Kodama, Christopher Lock, Erin E Longbrake, Bruno Musch, Gabriel Pardo, Fredrik Piehl, Martin S Weber, Steven Yuen, Tjalf Ziemssen
Biomarkers distinguishing nonrelapsing progressive disease biology from relapsing biology in multiple sclerosis (MS) are lacking. Cerebrospinal fluid (CSF) is an accessible fluid that most closely reflects central nervous system biology.
-
Treatment of Refractory Status Epilepticus With Continuous Intravenous Anesthetic Drugs: A Systematic Review. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-11 Yu Kan Au, Mohammed F Kananeh, Rahul Rahangdale, Timothy Eoin Moore, Gregory A Panza, Nicolas Gaspard, Lawrence J Hirsch, Andres Fernandez, Syed Omar Shah
Multiple continuous intravenous anesthetic drugs (CIVADs) are available for the treatment of refractory status epilepticus (RSE). There is a paucity of data comparing the different types of CIVADs used for RSE.
-
Microbleeds in Heterozygous HTRA1-Related Cerebral Small Vessel Disease. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-11 Yu Guo, Qing Peng, Chen Ling
This case report describes the evaluation of a 44-year-old man with a history of headache, dizziness, and imbalance and imaging that showed lacunar infarctions and bilateral white matter hyperintensities.
-
Coma Prognostication After Acute Brain Injury: A Review. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 David Fischer, Brian L Edlow
Among the most impactful neurologic assessments is that of neuroprognostication, defined here as the prediction of neurologic recovery from disorders of consciousness caused by severe, acute brain injury. Across a range of brain injury etiologies, these determinations often dictate whether life-sustaining treatment is continued or withdrawn; thus, they have major implications for morbidity, mortality
-
Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 Daniela Renedo, Julian N Acosta, Audrey C Leasure, Richa Sharma, Harlan M Krumholz, Adam de Havenon, Fares Alahdab, Aleksandr Y Aravkin, Zahra Aryan, Till Winfried Bärnighausen, Sanjay Basu, Katrin Burkart, Kaleb Coberly, Michael H Criqui, Xiaochen Dai, Rupak Desai, Samath Dhamminda Dharmaratne, Rajkumar Doshi, Islam Y Elgendy, Valery L Feigin, Irina Filip, Mohamed M Gad, Sherief Ghozy, Nima Hafezi-Nejad
Stroke is a leading cause of death and disability in the US. Accurate and updated measures of stroke burden are needed to guide public health policies.
-
Wildfire Smoke and Its Neurological Impact. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 Hao Chen, Haiyan Tong, Yunan Xu
This Viewpoint calls for a more concerted research effort aimed at establishing a robust link between wildfire smoke exposure and neurological effects.
-
LDL-C Levels and Bleeding Risk in Patients Taking DAPT After Minor Ischemic Stroke or TIA. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 Aichun Cheng, Jing Xue, Anxin Wang, Qin Xu, Zhiyuan Feng, Jinxi Lin, Hao Li, Xia Meng, Jie Xu, Yongjun Wang
Evidence on the bleeding risk associated with low-density lipoprotein cholesterol (LDL-C) levels in patients receiving dual antiplatelet therapy (DAPT) remains sparse.
-
Male Carrier of X-Linked Adrenal Leukodystrophy Due to 47, XXY Karyotype. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 Yu Ni, Chen Liu, Liang Tan
This case report studies a 12-year-old boy with a family history of X-linked adrenal leukodystrophy and his 8-year-old younger brother.
-
Batoclimab vs Placebo for Generalized Myasthenia Gravis: A Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-03-04 Chong Yan, Yaoxian Yue, Yuzhou Guan, Bitao Bu, Qing Ke, Ruisheng Duan, Hui Deng, Qun Xue, Haishan Jiang, Fei Xiao, Huan Yang, Ting Chang, Zhangyu Zou, Haifeng Li, Song Tan, Haibing Xiao, Hongyu Zhou, Hua Zhang, Qiang Meng, Wenyu Li, Wei Li, Junhong Guo, Yali Zhang, Zunbo Li, Jianglong Tu, Jianquan Shi, Wei Li, Michael Lee, Yu Chen, Xiaolu Tao, Shuai Zhao, Ping Li, Chongbo Zhao
Myasthenia gravis (MG) is caused by autoantibodies that disrupt the neuromuscular junction. The neonatal fragment crystallizable receptor (FcRn) antagonists, efgartigimod and rozanolixizumab, reduce immunoglobulin G (IgG) level in the circulation and alleviate symptoms in patients with generalized MG.
-
Origin of Transthyretin in Cerebral Amyloid Angiopathy. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-26 Toshiya Nomura, Yohei Misumi, Masayoshi Tasaki, Konen Obayashi, Taro Yamashita, Yukio Ando, Mitsuharu Ueda
This case series evaluates the correlation between transthyretin and cerebral amyloid angiopathy progression in individuals with hereditary transthyretin amyloidosis.
-
Posttraumatic Epilepsy and Dementia Risk. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-26 Andrea L C Schneider, Connor A Law, Rebecca F Gottesman, Gregory Krauss, Juebin Huang, Anna Kucharska-Newton, Frances E Jensen, James J Gugger, Ramon Diaz-Arrastia, Emily L Johnson
Although both head injury and epilepsy are associated with long-term dementia risk, posttraumatic epilepsy (PTE) has only been evaluated in association with short-term cognitive outcomes.
-
Functional Outcomes in Conservatively vs Surgically Treated Cerebellar Infarcts. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-26 Sae-Yeon Won, Silvia Hernández-Durán, Bedjan Behmanesh, Joshua D Bernstock, Marcus Czabanka, Nazife Dinc, Daniel Dubinski, Thomas M Freiman, Albrecht Günther, Kara Hellmuth, Eva Herrmann, Juergen Konczalla, Ilko Maier, Ruzanna Melkonian, Dorothee Mielke, Paul Naser, Veit Rohde, Christian Senft, Alexander Storch, Andreas Unterberg, Johannes Walter, Uwe Walter, Matthias Wittstock, Jan Hendrik Schaefer
According to the current American Heart Association/American Stroke Association guidelines, decompressive surgery is indicated in patients with cerebellar infarcts that demonstrate severe cerebellar swelling. However, there is no universal definition of swelling and/or infarct volume(s) available to support a decision for surgery.
-
Paused-A Residency Interrupted. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-26 Elle Maureen Newcome
This essay describes the author’s experience with a biking accident.
-
Sublingual Edaravone Dexborneol for the Treatment of Acute Ischemic Stroke: The TASTE-SL Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-19 Yu Fu, Anxin Wang, Renhong Tang, Shuya Li, Xue Tian, Xue Xia, Jinsheng Ren, Shibao Yang, Rong Chen, Shunwei Zhu, Xiaofei Feng, Jinliang Yao, Yan Wei, Xueshuang Dong, Yun Ling, Fei Yi, Qian Deng, Cunju Guo, Yi Sui, Shugen Han, Guoqiang Wen, Chuanling Li, Aiqin Dong, Xin Sun, Zhimin Wang, Xueying Shi, Bo Liu, Dongsheng Fan
Sublingual edaravone dexborneol, which can rapidly diffuse and be absorbed through the oral mucosa after sublingual exposure, is a multitarget brain cytoprotection composed of antioxidant and anti-inflammatory ingredients edaravone and dexborneol.
-
Diagnosing Preclinical and Prodromal Neurodegenerative Diseases-The Clinical Is Political. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-19 Claire M Erickson, Emily A Largent
This Viewpoint describes clinical and political considerations for individuals diagnosed with neurodegenerative conditions during the preclinical or prodromal stage.
-
Highly Effective Therapies as First-Line Treatment for Pediatric-Onset Multiple Sclerosis. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-12 Nail Benallegue, Fabien Rollot, Sandrine Wiertlewski, Romain Casey, Marc Debouverie, Anne Kerbrat, Jérôme De Seze, Jonathan Ciron, Aurelie Ruet, Pierre Labauge, Elisabeth Maillart, Helene Zephir, Caroline Papeix, Gilles Defer, Christine Lebrun-Frenay, Thibault Moreau, Eric Berger, Bruno Stankoff, Pierre Clavelou, Olivier Heinzlef, Jean Pelletier, Eric Thouvenot, Abdullatif Al Khedr, Bertrand Bourre
Moderately effective therapies (METs) have been the main treatment in pediatric-onset multiple sclerosis (POMS) for years. Despite the expanding use of highly effective therapies (HETs), treatment strategies for POMS still lack consensus.
-
Shifting Carotid Web Due to a Wandering and Rotating Carotid Artery. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-12 Unal Mutlu, Willem Jan R Fokkink, Fop van Kooten
This case report describes the finding of a carotid web in combination with a wandering and rotating carotid artery, resulting in a stroke.
-
Trends in AVM-Associated Intracranial Hemorrhage in the United States, 2000-2019. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-12 Alexandra Giantini-Larsen, Cenai Zhang, Philip Stieg, Hooman Kamel
This cross-sectional study examines whether there has been a significant change in the annual incidence of arteriovenous malformation (AVM)–associated intracranial hemorrhage among US adults over the past 2 decades.
-
Revisiting the Emergency Department. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-12 Blake Thomson
This essay describes the author’s first time in an emergency department since accompanying his mother for neurologic evaluation.
-
Time to Anticoagulation Reversal and Outcomes After Intracerebral Hemorrhage. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-09 Kevin N Sheth, Nicole Solomon, Brooke Alhanti, Steven R Messe, Ying Xian, Deepak L Bhatt, J Claude Hemphill, Jennifer A Frontera, Raymond C Chang, Ilya M Danelich, Joanna Huang, Lee Schwamm, Eric E Smith, Joshua N Goldstein, Brian Mac Grory, Gregg C Fonarow, Jeffrey L Saver
Intracerebral hemorrhage (ICH) is the deadliest stroke subtype, and mortality rates are especially high in anticoagulation-associated ICH. Recently, specific anticoagulation reversal strategies have been developed, but it is not clear whether there is a time-dependent treatment effect for door-to-treatment (DTT) times in clinical practice.
-
Endovascular Thrombectomy Treatment Effect in Direct vs Transferred Patients With Large Ischemic Strokes: A Prespecified Analysis of the SELECT2 Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-08 Amrou Sarraj, Michael D Hill, M Shazam Hussain, Michael G Abraham, Santiago Ortega-Gutierrez, Michael Chen, Scott E Kasner, Leonid Churilov, Deep K Pujara, Hannah Johns, Spiros Blackburn, Sophia Sundararajan, Yin C Hu, Nabeel A Herial, Ronald F Budzik, William J Hicks, Juan F Arenillas, Jenny P Tsai, Osman Kozak, Dennis J Cordato, Ricardo A Hanel, Teddy Y Wu, Pere Cardona Portela, Chirag D Gandhi,
Patients with large ischemic core stroke have poor clinical outcomes and are frequently not considered for interfacility transfer for endovascular thrombectomy (EVT).
-
Healthy Lifestyle and Cognition in Older Adults With Common Neuropathologies of Dementia. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-05 Klodian Dhana, Puja Agarwal, Bryan D James, Sue E Leurgans, Kumar B Rajan, Neelum T Aggarwal, Lisa L Barnes, David A Bennett, Julie A Schneider
A healthy lifestyle is associated with better cognitive functioning in older adults, but whether this association is independent of the accumulation of dementia-related pathologies in the brain is uncertain.
-
Risk of Stroke and Myocardial Infarction Among Initiators of Triptans. JAMA Neurol. (IF 29.0) Pub Date : 2024-02-05 Christian Lund Petersen, Anders Hougaard, David Gaist, Jesper Hallas
Triptans are contraindicated in patients with ischemic heart disease or previous myocardial infarction, and caution is advised when prescribing these drugs to patients with vascular risk factors. However, controlled observational studies have either shown no association or an apparent lower risk, possibly owing to a channeling of triptans to individuals at low risk of cardiovascular outcomes, and it
-
Is Incidentally Discovered Covert Cerebrovascular Disease Ignorable? JAMA Neurol. (IF 29.0) Pub Date : 2024-02-05 Thomas R Meinel, Joanna M Wardlaw, David M Kent
This Viewpoint discusses the clinical implications of incidentally discovered covert cerebrovascular disease.
-
Endovascular Treatment of Acute Ischemic Stroke After Cardiac Interventions in the United States. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-29 Adam de Havenon, Lily W Zhou, Andrew B Koo, Charles Matouk, Guido J Falcone, Richa Sharma, John Ney, Liqi Shu, Shadi Yaghi, Hooman Kamel, Kevin N Sheth
Ischemic stroke is a serious complication of cardiac intervention, including surgery and percutaneous procedures. Endovascular thrombectomy (EVT) is an effective treatment for ischemic stroke and may be particularly important for cardiac intervention patients who often cannot receive intravenous thrombolysis.
-
Multiomic Analysis of Neuroinflammation and Occult Infection in Sudden Infant Death Syndrome. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-29 Prashanth S Ramachandran, Benjamin W Okaty, Molly Riehs, Anne Wapniarski, Daniel Hershey, Hani Harb, Maham Zia, Elisabeth A Haas, Sanda Alexandrescu, Lynn A Sleeper, Sara O Vargas, Mark P Gorman, Steven Campman, Othon J Mena, Keith Levert, Keith Hyland, Richard D Goldstein, Michael R Wilson, Robin L Haynes
Antemortem infection is a risk factor for sudden infant death syndrome (SIDS)-the leading postneonatal cause of infant mortality in the developed world. Manifestations of infection and inflammation are not always apparent in clinical settings or by standard autopsy; thus, enhanced resolution approaches are needed.
-
Building CRISPR Gene Therapies for the Central Nervous System: A Review. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-29 Sally E Salomonsson, Claire D Clelland
Gene editing using clustered regularly interspaced short palindromic repeats (CRISPR) holds the promise to arrest or cure monogenic disease if it can be determined which genetic change to create without inducing unintended cellular dysfunction and how to deliver this technology to the target organ reliably and safely. Clinical trials for blood and liver disorders, for which delivery of CRISPR is not
-
Diffusely Enhancing Lesions on MRI in DPPX Antibody-Associated Encephalitis. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-22 Mao Liu, Chuan Qin, Dai-Shi Tian
This case report describes a diagnosis of dipeptidyl-peptidaselike protein-6 antibody-associated encephalitis in a woman aged 51 years who presented with progressive gait instability, memory impairment, and weight loss.
-
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-22 Nicholas J Ashton, Wagner S Brum, Guglielmo Di Molfetta, Andrea L Benedet, Burak Arslan, Erin Jonaitis, Rebecca E Langhough, Karly Cody, Rachael Wilson, Cynthia M Carlsson, Eugeen Vanmechelen, Laia Montoliu-Gaya, Juan Lantero-Rodriguez, Nesrine Rahmouni, Cecile Tissot, Jenna Stevenson, Stijn Servaes, Joseph Therriault, Tharick Pascoal, Alberto Lleó, Daniel Alcolea, Juan Fortea, Pedro Rosa-Neto, Sterling
Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests.
-
Concomitant Medications for Progressive Supranuclear Palsy: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-22 Jay M Iyer, Douglas Gunzler, Anthony E Lang, Lawrence I Golbe, Alexander Pantelyat, Adam L Boxer, Anne-Marie Wills
This secondary analysis of a randomized clinical trial examines changes in the progression of progressive supranuclear palsy (PSP) associated with 31 concomitant medication classes used by study participants over 1 year.
-
Allogeneic Stem Cell Therapy for Acute Ischemic Stroke: The Phase 2/3 TREASURE Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-16 Kiyohiro Houkin, Toshiya Osanai, Shinichiro Uchiyama, Kazuo Minematsu, Akihiko Taguchi, Katsuhiko Maruichi, Yoshimasa Niiya, Katsuyuki Asaoka, Yoshihiro Kuga, Katsumi Takizawa, Koichi Haraguchi, Shinichi Yoshimura, Kazumi Kimura, Koji Tokunaga, Atsuo Aoyama, Fusao Ikawa, Chikanori Inenaga, Tatsuya Abe, Atsushi Tominaga, Shinichi Takahashi, Kohsuke Kudo, Miki Fujimura, Taku Sugiyama, Masaki Ito, Masahito
Cell therapy is a promising treatment approach for stroke and other diseases. However, it is unknown whether MultiStem (HLCM051), a bone marrow-derived, allogeneic, multipotent adult progenitor cell product, has the potential to treat ischemic stroke.
-
Psychedelics in Addiction Treatment-Navigating a Sociopolitical Rift. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-16 Nicky J Mehtani, Brian T Anderson, Jennifer M Mitchell
This Viewpoint discusses the use of psychedelics in treatment for substance use disorders.
-
SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-16 Alice Grizzel Willison, Marc Pawlitzki, Michael Peter Lunn, Hugh John Willison, Hans-Peter Hartung, Sven Günther Meuth
The temporal association between the occurrence of neurological diseases, many autoimmune diseases, and vaccination against SARS-CoV-2 has been topically interesting and remains hotly debated both in the medical literature and the clinic. Given the very low incidences of these events both naturally occurring and in relation to vaccination, it is challenging to determine with certainty whether there
-
Argatroban in Patients With Acute Ischemic Stroke With Early Neurological Deterioration: A Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-08 Xuting Zhang, Wansi Zhong, Rui Xue, Haidi Jin, Xiaoxian Gong, Yuhui Huang, Fujian Chen, Mozi Chen, Liqun Gu, Yebo Ge, Xiaodong Ma, Bifeng Zhong, Mengjie Wang, Haitao Hu, Zhicai Chen, Shenqiang Yan, Yi Chen, Xin Wang, Xiaoling Zhang, Dongjuan Xu, Yuping He, Minfang Lou, Aiju Wang, Xiong Zhang, Li Ma, Xiaodong Lu, Jianer Wang, Qiong Lou, Ping'an Qian, Guomin Xie, Xiaofen Zhu, Songbin He, Jin Hu, Xiongjie
The effect of argatroban in patients with acute ischemic stroke (AIS) and early neurological deterioration (END) is unknown.
-
Ophthalmoplegia With Isolated Extraocular Muscle Hypertrophy. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-08 Cathy Meng Fei Li, David Dongkyung Kim, Larry H Allen
A 60-year-old man is experiencing diplopia but no problems with visual acuity, pain, or other symptoms. A magnetic resonance image of the head shows abnormal thickening and T2 hyperintensity of the right lateral rectus muscle. What is your diagnosis?
-
Neurologic Alternative Payment Models-Bridging the Gap. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-08 Joseph T Kannarkat, George T Kannarkat, Lyell K Jones
This Viewpoint discusses alternative payments models and the responsibilities of health care professionals.
-
Trigeminal Ganglionopathy on Brain Magnetic Resonance Imaging-A Rare Etiology. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-08 Noel William Gomes, Rahul Tryambak Chakor, Swaleha Nadaf
This case report describes a 56-year-old man with periorbital swelling and hyperpigmentation on the right side of the face and a hypopigmented patch on the anterior chest.
-
The Perils and Pitfalls of Global Engagement. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-02 Melody T Asukile, Deanna R Saylor, Gretchen L Birbeck
This Viewpoint describes ways to improve global collaboration among neurologists.
-
Thrombectomy With the pRESET vs Solitaire Stent Retrievers as First-Line Large Vessel Occlusion Stroke Treatment: A Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-02 Raul G Nogueira, Donald Lobsien, Joachim Klisch, Daniel Pielenz, Elmar Lobsien, Eric Sauvageau, Nima Aghaebrahim, Markus Möhlenbruch, Dominik Vollherbst, Christian Ulfert, Hormozd Bozorgchami, Wayne Clark, Ryan Priest, Edgar A Samaniego, Santiago Ortega-Gutierrez, Malik Ghannam, Demetrius Lopes, Joshua Billingsley, Kiffon Keigher, Diogo C Haussen, Alhamza R Al-Bayati, Adnan Siddiqui, Elad Levy, Michael
Stent retriever-based thrombectomy is highly beneficial in large vessel occlusion (LVO) strokes. Many stent retriever designs are currently available, but comparison of these technologies in well-conducted studies is lacking.
-
Punctate Diffuse Cortex Signals in Creutzfeldt-Jakob Disease. JAMA Neurol. (IF 29.0) Pub Date : 2024-01-02 Zhongyun Chen, Yu Kong, Liyong Wu
This case report describes 2 patients with genetic Creutzfeldt-Jakob disease with atypical changes on diffusion-weighted imaging.
-
Retinal Hemorrhage Associated with Human Granulocytic Anaplasmosis. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-26 Kathryn N Lynch, Bimala Upadhyaya, Riwaj Bhagat
This case report describes a 51-year-old female with presented to the emergency department with high-grade fever, headache, nausea, vomiting, dizziness, diffuse arthralgias, and new-onset worsened vision that had developed over 3 days.
-
Looking Beyond Syndrome-Based Criteria for Autoimmune Encephalitis-The Need for Complementary Neural Antibody-Based Diagnostic Criteria. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-26 Adrian Budhram, Sarosh R Irani, Eoin P Flanagan
This Viewpoint discusses how neural antibody–based diagnostic criteria for autoimmune encephalitis would complement the syndrome-based diagnostic algorithm to improve sensitivity while maintaining high specificity.
-
Risk Factors for Young-Onset Dementia in the UK Biobank. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-26 Stevie Hendriks, Janice M Ranson, Kirsten Peetoom, Ilianna Lourida, Xin You Tai, Marjolein de Vugt, David J Llewellyn, Sebastian Köhler
There is limited information on modifiable risk factors for young-onset dementia (YOD).
-
Cerebral Amyloid Angiopathy and Risk of Isolated Nontraumatic Subdural Hemorrhage. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-26 Cyprien A Rivier, Hooman Kamel, Kevin N Sheth, Costantino Iadecola, Ajay Gupta, Mony J de Leon, Elizabeth Ross, Guido J Falcone, Santosh B Murthy
Cerebral amyloid angiopathy (CAA) is a common cause of spontaneous intracerebral hemorrhage in older patients. Although other types of intracranial hemorrhage can occur in conjunction with CAA-related intracerebral hemorrhage, the association between CAA and other subtypes of intracranial hemorrhage, particularly in the absence of intracerebral hemorrhage, remains poorly understood.
-
Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-18 Wagner S Brum, Kieran F Docherty, Nicholas J Ashton, Henrik Zetterberg, Oskar Hansson, John J V McMurray, Kaj Blennow
This exploratory analysis of a randomized clinical trial evaluates the effect of neprilysin inhibition on Alzheimer disease blood biomarkers in patients with heart disease.
-
Direct to Consumer Biomarker Testing for Alzheimer Disease-Are We Ready for the Insurance Consequences? JAMA Neurol. (IF 29.0) Pub Date : 2023-12-18 Jalayne J Arias, Margaret Manchester, James Lah
This Viewpoint discusses direct-to-consumer biomarker tests for Alzheimer disease and their implications on future insurance coverage.
-
A 51-Year-Old Woman With Abnormal Corpus Callosum Signal. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-18 Nina Xie, Qiying Sun
A 51-year-old woman presented with a 2-year history of progressive memory loss and left limb numbness. Imaging showed multifocal restricted diffusion in the corpus callosum and diffuse subcortical white matter hyperintensities and corpus callosum atrophy. What is your diagnosis?
-
Hypothermia vs Normothermia in Patients With Cardiac Arrest and Nonshockable Rhythm: A Meta-Analysis. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-18 Fabio Silvio Taccone, Josef Dankiewicz, Alain Cariou, Gisela Lilja, Pierre Asfar, Jan Belohlavek, Thierry Boulain, Gwenhael Colin, Tobias Cronberg, Jean-Pierre Frat, Hans Friberg, Anders M Grejs, Guillaume Grillet, Patrick Girardie, Matthias Haenggi, Jan Hovdenes, Janus Christian Jakobsen, Helena Levin, Hamid Merdji, Hassane Njimi, Paolo Pelosi, Christian Rylander, Manoj Saxena, Matt Thomas, Paul J
International guidelines recommend body temperature control below 37.8 °C in unconscious patients with out-of-hospital cardiac arrest (OHCA); however, a target temperature of 33 °C might lead to better outcomes when the initial rhythm is nonshockable.
-
How Much Good I Can Afford. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-11 Xinran Maria Xiang
This essay describes the author’s experience balancing the different necessities in medical practice, in particular writing perfect patient notes vs establishing a face-to-face connection.
-
Ownership and Interoperability Challenges of Alzheimer Monoclonal Antibody Registries. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-11 Mariana P Socal, Ilina C Odouard, Hadi Kharrazi
This Viewpoint addresses the challenges that the Centers for Medicare and Medicaid Services faces to collect real-world data on the effectiveness and safety of lecanemab from external registries to achieve its coverage with evidence development objectives.
-
Diagnostic Performance of Cortical Lesions and the Central Vein Sign in Multiple Sclerosis. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-11 Alessandro Cagol, Rosa Cortese, Muhamed Barakovic, Sabine Schaedelin, Esther Ruberte, Martina Absinta, Frederik Barkhof, Massimiliano Calabrese, Marco Castellaro, Olga Ciccarelli, Sirio Cocozza, Nicola De Stefano, Christian Enzinger, Massimo Filippi, Maciej Jurynczyk, Pietro Maggi, Nima Mahmoudi, Silvia Messina, Xavier Montalban, Jacqueline Palace, Giuseppe Pontillo, Anne-Katrin Pröbstel, Maria A Rocca
Multiple sclerosis (MS) misdiagnosis remains an important issue in clinical practice.
-
Change in Epidemiology of Creutzfeldt-Jakob Disease in the US, 2007-2020. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-11 Matthew A Crane, Sameer Nair-Desai, Alison Gemmill, John A Romley, John C Probasco
This cross-sectional study uses Centers for Disease Control and Prevention multiple cause of death data to examine recent US trends in Creutzfeldt-Jakob disease.
-
Neuronally Derived Extracellular Vesicle α-Synuclein as a Serum Biomarker for Individuals at Risk of Developing Parkinson Disease. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-04 Shijun Yan, Cheng Jiang, Annette Janzen, Thomas R Barber, Aline Seger, Michael Sommerauer, Jason J Davis, Kenneth Marek, Michele T Hu, Wolfgang H Oertel, George K Tofaris
Nonmotor symptoms of Parkinson disease (PD) often predate the movement disorder by decades. Currently, there is no blood biomarker to define this prodromal phase.
-
Mirror Hand Movements Caused by a Deletion of the DCC Gene. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-04 Lotte Kleinendorst, Mieke M van Haelst
This case report describes the evaluation of 16-year-old twins with chromosomal microarray and mirror movements.
-
Plasma Biomarker Strategy for Selecting Patients With Alzheimer Disease for Antiamyloid Immunotherapies. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-04 Niklas Mattsson-Carlgren, Lyduine E Collij, Erik Stomrud, Alexa Pichet Binette, Rik Ossenkoppele, Ruben Smith, Linda Karlsson, Juan Lantero-Rodriguez, Anniina Snellman, Olof Strandberg, Sebastian Palmqvist, Nicholas J Ashton, Kaj Blennow, Shorena Janelidze, Oskar Hansson
Antiamyloid immunotherapies against Alzheimer disease (AD) are emerging. Scalable, cost-effective tools will be needed to identify amyloid β (Aβ)-positive patients without an advanced stage of tau pathology who are most likely to benefit from these therapies. Blood-based biomarkers might reduce the need to use cerebrospinal fluid (CSF) or positron emission tomography (PET) for this.
-
Trends in Traumatic Brain Injury Mortality in the US. JAMA Neurol. (IF 29.0) Pub Date : 2023-12-04 Noor F Shaik, Connor A Law, Holly Elser, Andrea L C Schneider
This cohort study characterizes US trends in traumatic brain injury–related mortality by age, sex, and race and ethnicity.
-
Potential Medicare and Medicaid Savings on Anti-CD20 Therapy for Multiple Sclerosis. JAMA Neurol. (IF 29.0) Pub Date : 2023-11-27 John Kim, Aaron S Kesselheim, Riley Bove, Jerry Avorn, Benjamin N Rome
This cross-sectional study compares price data for ocrelizumab and rituximab to estimate the savings to Medicare and Medicaid if rituximab were used in the treatment of multiple sclerosis instead of the higher-priced ocrelizumab.
-
Alberta Stroke Program Early Computed Tomography Score, Infarct Core Volume, and Endovascular Therapy Outcomes in Patients With Large Infarct: A Secondary Analysis of the ANGEL-ASPECT Trial. JAMA Neurol. (IF 29.0) Pub Date : 2023-11-27 Dapeng Sun, Xu Guo, Thanh N Nguyen, Yuesong Pan, Gaoting Ma, Xu Tong, Raynald, Mengxing Wang, Ning Ma, Feng Gao, Dapeng Mo, Xiaochuan Huo, Zhongrong Miao
Endovascular therapy (EVT) demonstrated better outcomes compared with medical management in recent randomized clinical trials (RCTs) of patients with large infarct.
-
A Young Woman With Hypertonia, Severe Scoliosis, and Encephalopathy. JAMA Neurol. (IF 29.0) Pub Date : 2023-11-27 Lei Hua, Yang Zhao, Yong-Shen Han
A 31-year-old woman was seen with contractures in her fingers and toes, carpal inversion, dysarthria, dysphagia, hypertonia, decreased tendon reflexes, absence of Babinski sign, and no psychiatric problems and significant global atrophy. What is your diagnosis?